Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Aug 20 · above the Ichimoku cloud · RSI 59 · MACD above its signal
None of the 29 investors followed here reported a position in CNBX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CNBX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CNBX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -62.5 | -33.3 | 0.0 | 100.0 | 0.0 | -25.0 | -33.3 | 40.0 | -28.6 | 100.0 | −50.0% | ||
| 2025 | 44.6 | -29.0 | 21.4 | -65.3 | -57.8 | -25.9 | -60.0 | 25.0 | -30.0 | 14.3 | 0.0 | 0.0 | −94.6% |
| 2024 | -28.9 | 18.8 | 32.5 | -7.5 | -38.8 | -36.7 | 16.7 | -6.8 | 12.9 | 12.9 | -5.1 | -1.3 | −47.9% |
| 2023 | -85.5 | -63.9 | -62.1 | -59.5 | 38.0 | -47.7 | 43.1 | 9.0 | 3.6 | -2.9 | -29.4 | 18.3 | −99.2% |
| 2022 | 10.1 | -7.5 | 9.7 | -10.9 | -46.7 | -29.2 | 13.6 | -15.4 | -5.9 | 19.5 | 3.5 | -53.0 | −80.3% |
| 2021 | 34.5 | 47.7 | -41.3 | -19.7 | -0.4 | -4.0 | -10.0 | 1.3 | -9.0 | -3.1 | -11.7 | -40.8 | −62.3% |
| 2020 | 328.8 | -42.8 | -40.0 | 20.8 | 25.3 | -12.9 | -15.7 | -4.5 | -13.6 | 14.3 | 58.8 | -30.4 | +70.1% |
| 2019 | 48.2 | -12.8 | -4.0 | -5.6 | -7.1 | -11.4 | -1.5 | -5.4 | -11.8 | -32.6 | -5.7 | -16.2 | −57.8% |
| 2018 | -6.6 | -34.3 | -0.9 | -3.6 | -4.7 | -10.9 | -10.6 | 13.1 | -18.5 | -25.8 | -19.1 | -34.8 | −84.0% |
| 2017 | 56.6 | 300.2 | -34.7 | -46.4 | -40.7 | 8.8 | 40.5 | -25.0 | -7.2 | -24.5 | 42.7 | 77.5 | +164.4% |
| 2016 | -8.3 | 100.0 | -26.1 | -5.2 | -5.1 | -24.9 | 2.0 | -2.1 | -5.5 | 1216.3 | 3.2 | 7.0 | +1156.0% |
| 2015 | 0.0 | -28.1 | 14.3 | -0.5 | -21.4 | 5.0 | -15.3 | 12.5 | -77.8 | 57.5 | -7.9 | -6.0 | −80.5% |
| 2014 | 0.0 | -14.3 | 0.0 | 166.7 | 150.0 | 140.0 | 6.3 | -2.0 | -30.0 | -20.0 | 0.0 | 0.0 | +700.0% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | -11.8 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 | 0.0 | -65.0 | −58.8% |
| 2012 | 0.0 | 0.0 | 7.7 | 78.6 | -20.0 | 0.0 | 25.0 | 0.0 | 0.0 | -20.0 | 0.0 | -15.0 | +30.8% |
| 2011 | -64.3 | 102.0 | -70.3 | 0.0 | 16.7 | 257.1 | -59.2 | -3.9 | -55.1 | 0.0 | 0.0 | -40.9 | −90.7% |
| 2010 | -44.4 | 0.0 | 20.0 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −22.2% |
| 2009 | 50.0 | 0.0 | -50.0 | 0.0 | 400.0 | -13.3 | -53.8 | 100.0 | -16.7 | 0.0 | 80.0 | 0.0 | +350.0% |
| 2008 | 35.0 | 0.0 | 0.0 | -3.7 | 0.0 | 0.0 | 3.8 | -3.7 | -73.1 | 0.0 | -28.6 | -60.0 | −90.0% |
| 2007 | 48.0 | -13.5 | -21.9 | -20.0 | 0.0 | −20.0% |
No analyst coverage for this instrument.
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
No recent headlines.